...
【24h】

On estimating medical cost and incremental cost-effectiveness ratios with censored data.

机译:通过审查的数据估算医疗成本和增量成本效益比。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Medical cost estimation is very important to health care organizations and health policy makers. We consider cost-effectiveness analysis for competing treatments in a staggered-entry, survival-analysis-based clinical trial. We propose a method for estimating mean medical cost over patients in such settings. The proposed estimator is shown to be consistent and asymptotically normal, and its asymptotic variance can be obtained. In addition, we propose a method for estimating the incremental cost-effectiveness ratio and for obtaining a confidence interval for it. Simulation experiments are conducted to evaluate our proposed methods. Finally, we apply our methods to a clinical trial comparing the cost effectiveness of implanted cardiac defibrillators with conventional therapy for individuals at high risk for ventricular arrhythmias.
机译:医疗费用估算对医疗保健组织和卫生政策制定者非常重要。我们在一项基于生存分析的交错式临床试验中考虑对竞争疗法进行成本效益分析。我们提出了一种在这种情况下估算患者平均医疗费用的方法。所提出的估计量被证明是一致且渐近正态的,并且可以获得其渐近方差。此外,我们提出了一种估算增量成本效益比并为其获得置信区间的方法。进行仿真实验以评估我们提出的方法。最后,我们将我们的方法应用于一项临床试验,该试验比较了植入式心脏除颤器与常规疗法对室性心律失常高风险人群的成本效益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号